ABOS

Acumen Pharmaceuticals, Inc.
CAPPED RATING

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Acumen Pharmaceuticals, Inc. (ABOS) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B+
Factor Score 3.7 / 5.0
Growth
B-
Factor Score 3.0 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D
Factor Score 1.5 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA 0.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -92.1%
Price Return 12M -88.1%
Catalyst Signal 0.00
Market Cap $15.6M
TTM Revenue N/A
Price / Sales N/A
ROE -162.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B+ (3.7) B- (3.0) C (2.2) D (1.5) F (0.0) C- (2.1)
2026-11-10 B+ (3.8) B- (3.0) C (2.2) D+ (1.7) F (0.0) C (2.2)
2026-11-03 B+ (3.7) B- (3.0) C (2.3) D+ (1.5) F (0.0) C- (2.1)
2026-10-27 C+ (2.5) D+ (1.7) C (2.4) C+ (2.6) C+ (2.6) C (2.4)
2026-10-20 C+ (2.5) C- (1.9) C (2.4) C (2.4) C+ (2.6) C (2.4)
Page 1 of 4